Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

Bullboard Posts

Post by grosdavidon May 13, 2020 12:54pm

178 Views

Post# 31023059

Patience pays off. Trust the facts not the doubters

They said that the PP would close May 12th, they said right and here we are today with close to 6,9 M$ less the fees owed to Mackie in the bank.

People jumped to buy and thats what happens when something is cooking in the background that we don't have/know the scale of what can be achieved in the next months. Blood bath today on the stock market, except for AGN.

Good day guys and hoping to hear an update tomorrow about the clinical trials.
David

Bullboard Posts

AI companies to invest in